MT1 vs MT2: Peptide Differences, Evidence and Identity

What is MT2, and how does it differ from MT1?

MT2, MT-II and melanotan II are names used for a synthetic cyclic peptide related to alpha-melanocyte-stimulating hormone, or alpha-MSH. Its seven-residue structure includes a bridge between amino-acid side chains. MT1, also written MT-I or melanotan I, refers to the alpha-MSH analogue associated with the name afamelanotide, a 13-residue peptide.

The distinction is chemical, not a strength setting. Replacing “I” with “II” does not mean doubling an amount, improving a formulation or creating an interchangeable substitute. The original MT-I study specifies the analogue by its amino-acid substitutions; the MT-II synthesis paper describes a different, cyclized molecule.

For research records, expand the abbreviation once and retain the exact identity specification. A short name is convenient in a notebook, but it is too little information to reconcile an ambiguous supplier document.

A comparison that keeps the categories straight

The table separates molecule-level facts from product-level claims. Read across each row before drawing a conclusion: a fact about one category cannot fill a gap in another.

What the early studies can—and cannot—tell you

The 1997 MT-I pharmacokinetic study involved three male volunteers and examined delivery routes, plasma measurements and pigmentation. It is useful historical evidence about a specific experimental material and study design. A three-person study is not a broad safety survey, and its route comparisons are not instructions for using current research products.

The 1996 MT-II pilot also enrolled three male volunteers. Its authors reported pigmentation observations alongside effects including nausea, fatigue and other systemic responses. Those findings matter because they prevent a skin-pigmentation endpoint from being mistaken for the full biological or safety profile.

Neither paper is a direct MT1-versus-MT2 trial. Putting their findings into adjacent spreadsheet columns does not create one. Different methods and endpoints remain different even when the publications discuss related molecules.

A more defensible research note has three fields: what was measured, in which population or model, and with which material. Leave a comparison unresolved when the studies do not support it. That is more useful than assigning a winner from unrelated experiments.

Why the afamelanotide approval needs its full name

EMA product information identifies Scenesse as an afamelanotide implant for preventing phototoxicity in adults with erythropoietic protoporphyria (EPP). It describes specialist prescribing and administration. That is a defined medicine, formulation and indication—not a general authorization for cosmetic tanning products.

Consider a hypothetical claim: “Afamelanotide is used in an approved medicine, so this MT1 research vial has the same status.” The conclusion changes the subject halfway through. Evidence about Scenesse does not establish the manufacturing, formulation, quality or authorization of another item. The same claim would be even less applicable to the chemically different MT2.

When an approval is cited, write down the medicine name, active substance, formulation, jurisdiction and indication. If the advertised item differs, the approval citation needs to be read within that narrower boundary.

A recent example of why labels need verification

In an August 2026 advisory, Australia’s TGA reported testing five seized nasal-spray bottles labeled with the same nominal Melanotan II amount. Estimated contents varied from 22 mg to 54 mg against a 30 mg label claim. The agency also stated that no Melanotan II products were included in the Australian Register of Therapeutic Goods at the time of the advisory.

This is evidence about the tested products, not a result for RetaSet inventory or every product using the name. Its practical lesson is narrower and valuable: matching labels did not establish matching contents in that investigation. A chemical name, a stated amount and measured sample content are separate claims.

For a laboratory purchase, request documentation tied to the supplied lot and the intended analytical question. Keep identity evidence, content measurements and purity results in separate fields. If a detail is missing, record the gap rather than filling it with a finding from a clinical paper.